Under the terms of the revenue purchase and sale agreement, the participants purchased a capped single-digit percentage revenue interest in net sales of tapinarof for all dermatological indications in the United States in exchange for $160 million in committed funding to be paid to Dermavant, subject to approval of tapinarof by the U.S. Food and Drug Administration (FDA). The company has previously reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis, and recently submitted a New Drug Application (NDA) for tapinarof to the FDA. The company intends to use the funding proceeds for the payment of certain one-time milestone obligations that become payable upon the approval and commercialization of tapinarof for the treatment of psoriasis in the United States, as well as for other general corporate purposes.
Concurrent with entering into the revenue sale transaction, Dermavant entered into a $40 million senior secured credit facility with the Boston-based investor. The loan proceeds were used to pay off the company’s previously existing secured credit facility, with the remainder of net proceeds to be used for working capital and general corporate purposes.
“These transactions will allow Dermavant to fully fund all milestone payments associated with the approval of tapinarof for the treatment of psoriasis in the U.S. and increase our investment in its commercial launch,” said Todd Zavodnick, Chief Executive Officer of Dermavant. “Following the recent NDA submission for tapinarof in plaque psoriasis, we plan to initiate a Phase 3 trial for the drug in atopic dermatitis in the second half of the year. Each of these milestones brings us closer to delivering this potential new therapy to patients who are suffering from these chronic skin diseases.”
“Our participation in the revenue sale transaction reflects our confidence in tapinarof, underlined by the drug’s five key attributes that were observed during the Phase 3 clinical trials for the treatment of psoriasis, including treatment effect, durability on-therapy, remittive effect off-therapy, safety, and tolerability,” said Steve DeNelsky, Managing Director at Marathon. “We believe that tapinarof, if approved by the FDA, could provide a meaningful new topical treatment option for healthcare providers and patients who otherwise have limited choices in therapies.”
“We are delighted to continue to play our part in Dermavant’s development as the company prepares for the commercial launch of tapinarof, potentially Dermavant’s first FDA-approved product,” said Brian Axe, Managing Director of NovaQuest. “We are confident that the company has the right team and strategy in place to commercialize this innovative therapy which, if approved, we believe could improve the standard of care for patients suffering from psoriasis and atopic dermatitis.”
Morgan Stanley & Co. LLC acted as Dermavant’s sole structuring agent on the revenue sale transaction and as sole placement agent on the senior debt financing. Cooley LLP acted as counsel to Dermavant, Pillsbury Winthrop Shaw Pittman LLP acted as counsel to the Boston-based institutional investor, Wyrick Robbins Yates & Ponton LLP acted as counsel to NovaQuest, and Latham & Watkins LLP acted as counsel to Marathon.
About Marathon Asset Management
Marathon Asset Management, L.P. is a New York-based global asset manager with over $22 billion of capital. Bruce Richards, Chief Executive Officer, and Louis Hanover, Chief Investment Officer, founded the firm in 1998, which currently employs 160 investment professionals. Marathon’s Healthcare Investment Team is led by Dr. Evan Bedil and is comprised of 15 professionals including four M.D.s and two PhDs. Marathon’s corporate headquarters are in New York City with international offices in London and Tokyo. Marathon is a Registered Investment Adviser with the Securities and Exchange Commission. For more information, please visit the company’s website at www.marathonfund.com
About NovaQuest Capital Management
Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate significantly higher than the industry average. Currently managing more than $2.2 billion in capital, NovaQuest is actively investing from the $1.2 billion Pharma Opportunities Fund V, evaluating global opportunities with financing needs that range from $30-100 million. For more information, please visit www.novaquest.com
Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company’s robust medical dermatology pipeline includes both late-stage and earlier-stage-development product candidates the company believes could address important immuno-dermatological conditions, including psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, and acne. Tapinarof is a novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 8 million and 26 million people in the United States, respectively. The company has reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis. For more information, please visit www.dermavant.com, and follow us on Twitter (@dermavant) and LinkedIn (Dermavant Sciences).